Half of England’s heart failure patients have spent decades watching the other half get all the drugs. That’s the context for what NICE did this week. On 16 July, the institute published final draft guidance recommending finerenone for adults with chronic heart failure with preserved or mildly reduced ejection fraction. NICE estimates up to 280,000 … Read more
NICE recommended 66 new treatments last year and rejected seven but 25 evaluations were terminated before anyone ruled on them.
Germany’s lawmakers had no shortage of warnings. Drugmakers objected. Trade groups objected. So did opposition voices inside the country’s own government. The reform passed anyway. Late on Friday, the Bundestag, Germany’s lower house of parliament, approved a health insurance financial reform package by 318 votes to 284, with four abstentions. That is not a comfortable … Read more
NICE has recommended routine NHS access to nusinersen and risdiplam for spinal muscular atrophy.
The EU’s Critical Medicines Act takes direct aim at the supply chain vulnerabilities that leave patients without essential drugs when it matters most.
The UK health watchdog National Institute for Health and Care Excellence (NICE) has recommended a suite of digital platforms to help people with asthma better manage their condition, signalling growing confidence in app-based tools as part of routine care, while stopping short of full endorsement pending further evidence. In draft guidance published yesterday, NICE said … Read more
Last week’s policy signals from Germany underscored a clear regulatory theme: access increasingly hinges on comparative evidence, not just innovation or unmet need. New assessments from the Institute for Quality and Efficiency in Health Care (IQWiG) highlighted where evidence is strong enough to support added benefit, where gaps remain despite growing treatment options. Multiple myeloma: … Read more
Eli Lilly and Company has entered a global strategic collaboration, licensing agreement, and equity investment with InduPro Therapeutics, betting up to $950 million on a proximity-guided approach to discover first-in-class bispecific and multispecific oncology therapeutics. Under the agreement, the companies will collaborate on up to three oncology targets, with Lilly also taking an equity stake … Read more
UK biotech Ikarovec teams with VectorBuilder on eye gene delivery.
NICE proposes age-based CA125 testing to improve early diagnosis.